who is developing retatrutide 🚨 JUST RELEASED TODAY!!!! NEW PHASE 3 DATA Today, July 23, 2026, new Phase 3 retatrutide results were released, adding to what already one of the most interesting obesity drug Retatrutide: What It Is Made

The key difference is dosing range

Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs

Is it beneficial for weight management and glycemic control

By that point in clinical trials , people with type 2 diabetes taking 14 mg of oral semaglutide (Rybelsus) were: Eating nearly 40% fewer calories per day Feeling less hungry and more in control of their appetite About 5 pounds lighter, mostly due to fat loss People who took a placebo, on the other hand, lost less than half a pound in the same time frame

If you are a medical aesthetician, you can help clients who want to look and feel their best after losing weight